Premium
Comparative efficacy and safety of palonosetron with the first 5‐HT3 receptor antagonists for the chemotherapy‐induced nausea and vomiting: a meta‐analysis
Author(s) -
JIN Y.,
SUN W.,
GU D.,
YANG J.,
XU Z.,
CHEN J.
Publication year - 2013
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/j.1365-2354.2012.01353.x
Subject(s) - palonosetron , medicine , nausea , chemotherapy induced nausea and vomiting , vomiting , granisetron , chemotherapy , oncology , anesthesia , pharmacology , gastroenterology , antiemetic
JIN Y., SUN W., GU D., YANG J., XU Z. & CHEN J. (2013) European Journal of Cancer Care 22 , 41–50 Comparative efficacy and safety of palonosetron with the first 5‐HT3 receptor antagonists for the chemotherapy‐induced nausea and vomiting: a meta‐analysis A number of studies have reported the difference between the 5‐HT3 receptor antagonists and palonosetron in preventing the chemotherapy‐induced nausea and vomiting (CINV). Through analysing the efficacy and safety in palonosetron‐treated patients, it can provide evidence for palonosetron administration. We identified randomised controlled clinical trials comparing palonosetron with the first‐generation 5‐HT3 receptor antagonists in the prevention of CINV in cancer patients. Nine studies investigated the outcomes in a total of 3463 cases. Compared with the first‐generation 5‐HT3 receptor antagonists, the cumulative incidences of emesis were significantly reduced in the patients treated with palonosetron (0.25 mg i.v.) on the first day [relative risk (RR) = 1.11, 95% confidence interval (CI): 1.05–1.17], from 2 to 5 days (RR = 1.26, 95% CI: 1.16–1.36) and the overall five days (RR = 1.23, 95% CI: 1.13–1.34). Regarding the drug safety, there was no significant difference between palonosetron‐treated group and the first‐generation 5‐HT3 receptor antagonists‐treated group. Results from the analysis suggest that palonosetron is highly effective in preventing nausea and vomiting in the days after administration of moderately or highly emetogenic chemotherapy agents.